The U.S. Food and Drug Administration (FDA) approved the first-ever treatment for BRAF V600E mutation-positive anaplastic thyroid cancer based on clinical trials conducted at MD Anderson.

Authors

• Person: Not available Organization: MD Anderson Cancer Center
  Clinical Center for Targeted Therapy | UT MD Anderson

Sources

• Clinical Center for Targeted Therapy | UT MD Anderson www.mdanderson.org MD Anderson Cancer Center via serper

Referenced by nodes (1)

• UT MD Anderson Cancer Center entity